What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Ambrosia Health announced on February 19, 2019, that it had stopped treating patients after the U.S. Food and Drug Administration warned consumers about plasma from young donors promoted for anti-aging and disease treatment. The FDA did not name Ambrosia in its warning, and officials said the promoted uses had no proven clinical benefit and could carry serious risks.
What happened to the young-blood transfusion startup?
Ambrosia Health offered intravenous infusions of plasma from donors aged 16 to 25. On February 19, 2019, the company posted: “In compliance with the FDA announcement issued February 19, 2019, we have ceased patient treatments,” according to CBS News.
CBS reported at the time that Ambrosia advertised one-liter and two-liter packages for $8,000 and $12,000, respectively, and appointments in five cities. Those were historical 2019 details, not current prices or evidence that the service is available today. The reporting reviewed here confirms the cessation announcement but does not establish Ambrosia’s present operating or corporate status.
Why did Ambrosia stop treatments?
The company said it was acting in compliance with the FDA announcement issued that day. The agency’s consumer warning addressed businesses offering plasma from young donors to prevent aging or treat conditions including memory loss, Alzheimer’s disease, Parkinson’s disease, and heart disease. Contemporaneous reports connected Ambrosia’s announcement to the warning, but the FDA did not identify Ambrosia by name.
Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstall#1 Best Overall
FDA Commissioner Scott Gottlieb and Peter Marks, then director of the FDA’s Center for Biologics Evaluation and Research, said: “There is no proven clinical benefit of infusion of plasma from young donors to cure, mitigate, treat, or prevent these conditions, and there are risks associated with the use of any plasma product.” They also urged consumers not to pursue the therapy outside clinical trials with appropriate institutional review board and regulatory oversight, as reported by TechCrunch.
Did the FDA say young-donor plasma infusions work?
No. FDA officials said there was no proven clinical benefit for the anti-aging and disease-treatment uses being promoted. They also said those uses had not gone through the rigorous testing normally used to establish a treatment’s benefit and safety. Contemporaneous coverage reported that Ambrosia’s study results had not been publicly released; the sources reviewed do not establish that later publication confirmed a benefit.
Rank #2
This warning concerned those promoted uses, not every medical use of plasma. CBS noted that plasma has established medical uses, including in trauma care and for people whose blood does not coagulate properly. Such uses do not establish that young-donor plasma prevents aging or treats the conditions named in the marketing.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What risks did the FDA identify?
The FDA warned that large-volume plasma infusions can be associated with infectious, allergic, respiratory, and cardiovascular risks. The warning is relevant to the infusion itself as well as to claims about its benefits: a treatment with unproven benefit can still expose a patient to meaningful harm.
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Repair Windows errors before they cause bigger problems3Scan for outdated or missing drivers - takes under a minuteThe FDA’s advice was to avoid pursuing the therapy outside clinical trials with appropriate institutional review board and regulatory oversight. That distinction matters: a properly overseen trial is designed to evaluate an investigational treatment; a commercial offering does not become proven or safe merely because it is available to purchase.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
